SCHEMBL6428332

SCHEMBL6428332

Cn1cc(NC(=O)OC(C)(C)C)nc1C(=O)Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.42
DYRK1A Q13627 1/20 0.42
ATR Q13535 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.36
P2RX7 Q99572 1/20 0.34
LCK P06239 3/20 0.34
SCN9A Q15858 1/20 0.34
CYP17A1 P05093 1/20 0.33
BRD4 O60885 1/20 0.33
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
PTGER1 P34995 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
MAPK14 Q16539 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1986577 0.87 GSK3B (0.43) GSK3BDYRK1AATRIRAK4P2RX7
SCHEMBL3418695 0.86 GSK3B (0.42) GSK3BDYRK1AATRIRAK4P2RX7
SCHEMBL18574435 0.86 GSK3B (0.42) GSK3BDYRK1AATRIRAK4LCK
SCHEMBL6428501 0.84 GSK3B (0.41) GSK3BDYRK1AATRIRAK4LCK
SCHEMBL2389887 0.82 GSK3B (0.40) GSK3BDYRK1AIRAK4P2RX7LCK
SCHEMBL2390936 0.82 GSK3B (0.40) GSK3BDYRK1AIRAK4P2RX7LCK
SCHEMBL18975727 0.82 GSK3B (0.40) GSK3BDYRK1AIRAK4LCKSCN9A
SCHEMBL3415059 0.81 GSK3B (0.39) GSK3BDYRK1AATRIRAK4LCK
SCHEMBL7079271 0.81 RPS6KA3 (0.43) GSK3BDYRK1AP2RX7KMT2A
SCHEMBL14926232 0.81 GSK3B (0.44) GSK3BDYRK1AATRIRAK4P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924396-B2 α-haloenamine reagents PHARMACIA CORPORATION (US) 2005-08-02 US disclosed
CN-1561326-A Alpha-haloenamine reagents PHARMACIA CORP (US) 2005-01-05 CN disclosed
EP-1430028-A2 AROMATIC AND HETEROAROMATIC ACID HALIDES FOR SYNTHESIZING POLYAMIDES Pharmacia Corporation (US) 2004-06-23 EP disclosed
EP-1421056-A1 (ALPHA)-HALOENAMINE REAGENTS Pharmacia Corporation (US) 2004-05-26 EP disclosed
US-20040092770-A1 Alpha-haloenamine reagents PHARMACIA CORPORATION 2004-05-13 US disclosed
US-6677487-B2 COMBINING A TERTIARY AMIDE WITH A PENTAVALENT PHOSPHOROUS HALIDE IN A SOLVENT TO FORM AN ALPHA - HALOIMINIUM SALT AND CONVERTING THE ALPHA -HALOIMINIUM SALT TO THE ALPHA -HALOENAMINE WITH A BASE PHARMACIA CORPORATION 2004-01-13 US disclosed
US-20030105279-A1 Aromatic and heteroaromatic acid halides for synthesizing polyamides PHARMACIA CORPORATION 2003-06-05 US disclosed
US-20030080320-A1 Alpha- haloenamine reagents PHARMACIA CORPORATION 2003-05-01 US disclosed
WO-2003020684-A1 (ALPHA)-HALOENAMINE REAGENTS PHARMACIA CORPORATION (US) 2003-03-13 WO disclosed
WO-2003018552-A2 AROMATIC AND HETEROAROMATIC ACID HALIDES FOR SYNTHESIZING POLYAMIDES PHARMACIA CORPORATION (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030080320-A1 Alpha- haloenamine reagents HNMT, HDHD5, NISCH GSK3B 2745/4885DYRK1A 1290/4885ATR 4102/4885
US-20040092770-A1 Alpha-haloenamine reagents HNMT, HDHD5, NISCH GSK3B 2745/4885DYRK1A 1290/4885ATR 4102/4885
US-20030105279-A1 Aromatic and heteroaromatic acid halides for synthesizing polyamides AAAS, HTT, HRH4 GSK3B 4778/4885DYRK1A 548/4885ATR 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.